Daratumumab (Darzalex®) is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain amyloidosis.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||03/09/2021|
|Rapid review completed||13/10/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of daratumumab compared with the current standard of care.|